PPIDT00009
Drug Information
| Name | Alteplase |
|---|---|
| Sequence | SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSERLKEAHVRLYPSSRCTSQHLLNRTVTDNMLCAGDTRSGGPQANLHDACQGDSGGPLVCLNDGRMTLVGIISWGLGCGQKDVPGVYTKVTNYLDWIRDNMRP |
| DrugBank_ID | DB00009 |
| Type | biotech |
| Indication | Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and acute pulmonary emboli accompanied by unstable hemodynamics.[L43125] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | — |
50 mg
|
| Injection, powder, for solution | Intravenous |
2 MG
|
| Injection, powder, for solution | Intravenous |
20 MG/20ML
|
| Injection, powder, for solution | Intravenous |
50 MG/50ML
|
| Solution | Intravenous |
20 MG
|
| Solution | Intravenous |
50 MG
|
| Solution | Intravenous |
50.0 mg
|
| Solution | Intravenous |
10 mg
|
| Injection, powder, for solution | Parenteral |
|
| Injection, powder, lyophilized, for solution | Intravenous |
50 MG/50ML
|
| Injection, powder, for solution | Intravenous |
50 mg
|
| Solution | Intravenous |
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
100 mg/100mL
|
| Injection, powder, lyophilized, for solution; kit | Intravenous |
50 mg/50mL
|
| Liquid; powder, for solution | Intravenous |
|
| Powder, for solution | Intravenous |
50 mg/50mL
|
| Powder, for solution | Intravenous |
2 mg / vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
2.2 mg/2mL
|
| Powder, for solution | Intravenous |
|
| Powder | — |
50 mg/1vial
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| target | P00747 | PLG | Plasminogen | Homo sapiens | activator | Link |
| target | P02671 | FGA | Fibrinogen alpha chain | Homo sapiens | binder | Link |
| target | P02679 | FGG | Fibrinogen gamma chain | Homo sapiens | binder | Link |
| target | P05121 | SERPINE1 | Plasminogen activator inhibitor 1 | Homo sapiens | unknown | Link |